293 related articles for article (PubMed ID: 20623786)
1. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer.
Everitt S; Herschtal A; Callahan J; Plumridge N; Ball D; Kron T; Schneider-Kolsky M; Binns D; Hicks RJ; MacManus M
Cancer; 2010 Nov; 116(21):5030-7. PubMed ID: 20623786
[TBL] [Abstract][Full Text] [Related]
2. Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
Geiger GA; Kim MB; Xanthopoulos EP; Pryma DA; Grover S; Plastaras JP; Langer CJ; Simone CB; Rengan R
Clin Lung Cancer; 2014 Jan; 15(1):79-85. PubMed ID: 24238934
[TBL] [Abstract][Full Text] [Related]
3. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
4. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and staging impact of radiotherapy planning FDG-PET-CT in non-small-cell lung cancer.
Lin P; Koh ES; Lin M; Vinod SK; Ho-Shon I; Yap J; Som S
Radiother Oncol; 2011 Nov; 101(2):284-90. PubMed ID: 21777988
[TBL] [Abstract][Full Text] [Related]
6. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment.
Mac Manus MP; Hicks RJ; Ball DL; Kalff V; Matthews JP; Salminen E; Khaw P; Wirth A; Rischin D; McKenzie A
Cancer; 2001 Aug; 92(4):886-95. PubMed ID: 11550162
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.
Kong FM; Frey KA; Quint LE; Ten Haken RK; Hayman JA; Kessler M; Chetty IJ; Normolle D; Eisbruch A; Lawrence TS
J Clin Oncol; 2007 Jul; 25(21):3116-23. PubMed ID: 17634490
[TBL] [Abstract][Full Text] [Related]
8. (18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT.
Hanna GG; McAleese J; Carson KJ; Stewart DP; Cosgrove VP; Eakin RL; Zatari A; Lynch T; Jarritt PH; Young VA; O'Sullivan JM; Hounsell AR
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):24-30. PubMed ID: 19665324
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
11. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
12. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study.
van Loon J; Grutters J; Wanders R; Boersma L; Oellers M; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Fatah SA; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2009 Mar; 45(4):588-95. PubMed ID: 19046631
[TBL] [Abstract][Full Text] [Related]
13. Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans.
Aristophanous M; Yong Y; Yap JT; Killoran JH; Allen AM; Berbeco RI; Chen AB
Radiother Oncol; 2012 Mar; 102(3):377-82. PubMed ID: 22265731
[TBL] [Abstract][Full Text] [Related]
14. Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy--a retrospective study.
Abramyuk A; Appold S; Zöphel K; Hietschold V; Baumann M; Abolmaali N
Lung Cancer; 2012 Nov; 78(2):148-52. PubMed ID: 22922126
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
[TBL] [Abstract][Full Text] [Related]
16. Rapid disease progression with delay in treatment of non-small-cell lung cancer.
Mohammed N; Kestin LL; Grills IS; Battu M; Fitch DL; Wong CY; Margolis JH; Chmielewski GW; Welsh RJ
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):466-72. PubMed ID: 20471184
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of 18F-fluorodeoxyglucose uptake by using serial positron emission tomography and computed tomography in patients with stage III nonsmall cell lung cancer.
Xu X; Yu J; Sun X; Yang G; Li K; Fu Z; Han A; Zheng J
Am J Clin Oncol; 2008 Oct; 31(5):470-5. PubMed ID: 18838884
[TBL] [Abstract][Full Text] [Related]
18. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
[TBL] [Abstract][Full Text] [Related]
19. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
20. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]